-
Ugeskrift For Laeger Aug 1984
Topics: Animals; Chemical Phenomena; Chemistry; Doxapram; Humans
PubMed: 6515869
DOI: No ID Found -
Chest Apr 2002
Clinical Trial
Topics: Adult; Doxapram; Dyspnea; Humans; Hypoxia; Male; Middle Aged; Oxygen; Respiratory System Agents; Risk Factors; Single-Blind Method; Work of Breathing
PubMed: 11948090
DOI: 10.1378/chest.121.4.1380 -
British Medical Journal (Clinical... Jan 1982
Topics: Anti-Bacterial Agents; Breathing Exercises; Doxapram; Drainage; Female; Humans; Male; Pneumonia; Postoperative Complications
PubMed: 6800435
DOI: 10.1136/bmj.284.6312.292 -
Neonatology 2020Evaluation of pharmacotherapy during intensive care treatment is commonly based on subjective, intermittent interpretations of physiological parameters. Real-time... (Observational Study)
Observational Study
INTRODUCTION
Evaluation of pharmacotherapy during intensive care treatment is commonly based on subjective, intermittent interpretations of physiological parameters. Real-time visualization and analysis may improve drug effect evaluation. We aimed to evaluate the effects of the respiratory stimulant doxapram objectively in preterm infants using continuous physiological parameters.
METHODS
In this longitudinal observational study, preterm infants who received doxapram therapy were eligible for inclusion. Physiological data (1 Hz) were used to assess respiration and to evaluate therapy effects. The oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio and the area under the 89% SpO2 curve (duration × saturation depth below target) were calculated as measures of hypoxemia. Regression analyses were performed in 1-h timeframes to discriminate therapy failure (intubation or death) from success (no intubation).
RESULTS
Monitor data of 61 patients with a median postmenstrual age (PMA) at doxapram initiation of 28.7 (IQR 27.6-30.0) weeks were available. The success rate of doxapram therapy was 56%. Doxapram pharmacodynamics were reflected in an increased SpO2 and SpO2/FiO2 ratio as well as a decrease in episodes with saturations below target (SpO2 <89%). The SpO2/FiO2 ratio, corrected for PMA and mechanical ventilation before therapy start, discriminated best between therapy failure and success (highest AUC ROC of 0.83).
CONCLUSION
The use of continuous physiological monitor data enables objective and detailed interpretation of doxapram in preterm infants. The SpO2/FiO2 ratio is the best predictive parameter for therapy failure or success. Further implementation of real-time data analysis and treatment algorithms would provide new opportunities to treat newborns.
Topics: Doxapram; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Oxygen; Respiratory System Agents
PubMed: 32841955
DOI: 10.1159/000509269 -
Anesthesiology 1963
Topics: Anesthesia; Anesthesia, Intravenous; Blood Pressure; Central Nervous System Stimulants; Doxapram; Electrocardiography; Electroencephalography; Humans; Pharmacology; Respiration; Respiratory System Agents; Thiopental
PubMed: 14071413
DOI: 10.1097/00000542-196311000-00010 -
Anaesthesia Jan 1983
Clinical Trial Randomized Controlled Trial
Topics: Abdomen; Clinical Trials as Topic; Cough; Double-Blind Method; Doxapram; Female; Humans; Lung Diseases; Male; Middle Aged; Postoperative Complications
PubMed: 6337526
DOI: 10.1111/j.1365-2044.1983.tb10364.x -
British Journal of Anaesthesia Feb 1978
Topics: Animals; Doxapram; Drug Interactions; Humans; Mice; Morphine; Rats; Respiration
PubMed: 626704
DOI: 10.1093/bja/50.2.205-b -
British Journal of Anaesthesia Sep 1977
Topics: Doxapram; Humans; Male; Morphine; Pentazocine; Respiration
PubMed: 911597
DOI: 10.1093/bja/49.9.952-a -
Peptides Nov 2005Doxapram causes panic anxiety in humans. To determine whether doxapram alters corticotropin-releasing factor (CRF) expression in the central nucleus of the amygdala...
Doxapram causes panic anxiety in humans. To determine whether doxapram alters corticotropin-releasing factor (CRF) expression in the central nucleus of the amygdala (CeA), paraventricular nucleus of hypothalamus (PVN), or bed nucleus of the stria terminalis (BNST), we used immunohistochemistry to measure CRF peptide in these brain areas after doxapram injection. Doxapram injection significantly increased CRF-like immunoreactivity (CRF-IR) within the CeA, but not in the BNST or PVN, and this increase was significant 2h after injection. In addition, doxapram significantly increased CRF mRNA expression within the CeA, and this was most prominent 30min after injection. These results suggest that doxapram selectively increases CRF expression within the CeA, and that this is mediated by increased CRF gene transcription. This increase in CRF-IR within the CeA might explain the doxapram-induced anxiety reaction.
Topics: Amygdala; Animals; Central Nervous System Stimulants; Corticotropin-Releasing Hormone; Doxapram; Gene Expression Regulation; Immunohistochemistry; In Situ Hybridization; Male; Panic Disorder; Paraventricular Hypothalamic Nucleus; RNA, Messenger; Rats; Rats, Sprague-Dawley; Septal Nuclei
PubMed: 16269353
DOI: 10.1016/j.peptides.2005.03.036 -
Acta Paediatrica (Oslo, Norway : 1992) Nov 2005To examine the relation of doxapram to a developmental score achieved by a structured telephone interview in a group of extremely-preterm-born children.
AIM
To examine the relation of doxapram to a developmental score achieved by a structured telephone interview in a group of extremely-preterm-born children.
METHODS
Parents of 88 children born extremely preterm were contacted by telephone and interviewed by a structured questionnaire (R-PDQ) when the corrected age of their child was 9-15 mo.
RESULTS
We found that doxapram treatment was associated with a deficit in age-adjusted R-PDQ score.
CONCLUSION
Doxapram may have a negative effect on neurodevelopmental outcome.
Topics: Case-Control Studies; Developmental Disabilities; Doxapram; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Linear Models; Male; Respiratory System Agents
PubMed: 16303710
DOI: 10.1080/08035250500254449